IGF-1 LR3 (long R3 insulin-like growth factor-1)
Muscle & Strength · Modified IGF-1 analog
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades IGF-1 LR3 (long R3 insulin-like growth factor-1) as D (2.9/10) based on weak evidence, med benefit magnitude, and a high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 2/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Used in cell culture research, diverted for performance use.
Studied, labeled, or reported-use context: Typical illicit: 20-50 mcg/day subQ — Research chem (not approved); banned sport; not individualized guidance.
What the evidence says
Used in cell culture research, diverted for performance use. Hypoglycemia is acute and potentially severe. Chronic IGF-1 signaling activation theoretically pro-oncogenic — longevity circles argue for LOWER IGF-1 for lifespan. Counterfeits and underdosed products rampant.
Mechanism
Modified IGF-1 with Arg3 substitution and N-terminal 13-aa extension; drastically reduced IGFBP binding — longer plasma half-life and higher bioavailability than native IGF-1
Studied, labeled, or reported dose & route
Typical illicit: 20-50 mcg/day subQ
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about IGF-1 LR3 (long R3 insulin-like growth factor-1)'s effects?
- Read Off Label rates the evidence for IGF-1 LR3 (long R3 insulin-like growth factor-1) as Weak and the benefit magnitude as med, producing an overall grade of D (2.9/10). Used in cell culture research, diverted for performance use.
- What safety findings are reported for IGF-1 LR3 (long R3 insulin-like growth factor-1)?
- IGF-1 LR3 (long R3 insulin-like growth factor-1) has a high risk profile in the database. High (hypoglycemia — shared with insulin pathway; tumor/oncogenesis concerns via sustained IGF-1R signaling) Legal status: Research chem (not approved); banned sport.
- What does the low Safety score for IGF-1 LR3 (long R3 insulin-like growth factor-1) represent?
- The Safety score is 2/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for IGF-1 LR3 (long R3 insulin-like growth factor-1)?
- Typical illicit: 20-50 mcg/day subQ This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does IGF-1 LR3 (long R3 insulin-like growth factor-1) work?
- Modified IGF-1 with Arg3 substitution and N-terminal 13-aa extension; drastically reduced IGFBP binding — longer plasma half-life and higher bioavailability than native IGF-1
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.